亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma

医学 耐受性 蕈样真菌病 内科学 耐火材料(行星科学) 皮肤T细胞淋巴瘤 不良事件通用术语标准 侵袭性淋巴瘤 不利影响 肿瘤科 胃肠病学 淋巴瘤 美罗华 天体生物学 物理
作者
Zhiyu Pang,Yupeng Wang,Zhaorui Liu,Shan Zhang,Chong Wei,Zhuofan Xu,Ziqian Wang,Hongyun Chen,Jie Liu,Wei Zhang
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:161 (9): 923-923 被引量:6
标识
DOI:10.1001/jamadermatol.2025.1926
摘要

Importance: Patients with relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL) have limited treatment options. Combining agents that target complementary oncogenic pathways may enhance efficacy while maintaining tolerability. Objective: To evaluate the safety and efficacy of linperlisib, a PI3Kδ inhibitor, combined with chidamide, a histone deacetylase inhibitor, in patients with r/r CTCL. Design, Setting, and Participants: This prospective, single-arm, phase 1 nonrandomized clinical trial with a 3 + 3 dose-escalation phase followed by dose expansion was conducted at a tertiary referral hospital in China from May 1, 2023, to March 6, 2025, with a median follow-up of 8.9 months (range, 1-21 months). It included patients with histologically confirmed advanced CTCL. All had an Eastern Cooperative Oncology Group performance status of 0 to 2 and received a median (range) of 3 (1-7) prior systemic therapies. Patients were enrolled consecutively based on eligibility. Interventions: Oral linperlisib administered once daily in escalating doses (40 mg, 60 mg, or 80 mg) plus chidamide, 20 mg, twice weekly. Treatment continued until progression, unacceptable toxic effects, or withdrawal. Main Outcomes and Measures: Primary outcomes were dose-limiting toxic effects, maximum tolerated dose, and objective response rate. Secondary outcomes included safety, progression-free survival, and disease control rate. Results: Of 22 patients (19 [86.4%] with mycosis fungoides, 3 [13.6%] with Sézary syndrome), 10 were female individuals (45.5%), and the median (range) age was 44 (27-71) years. No dose-limiting toxic effects were observed. The recommended phase 2 dose of linperlisib was 80 mg. The most common treatment-related adverse events were nausea (8 [36.4%]), pruritus (7 [31.8%]), and skin rash (6 [27.3%]), mostly grade 1 to 2. Grade 3 adverse events occurred in 5 patients (22.7%); no grade 4 to 5 events were reported. The objective response rate was 59.1% (13 of 22; 95% CI, 38.7%-76.7%), including 2 complete responses and 11 partial responses. The disease control rate was 86.4% (19 of 22), and the median progression-free survival was 5.4 months. Conclusions and Relevance: This nonrandomized clinical trial found that plus chidamide showed a manageable safety profile and promising activity in r/r CTCL. This all-oral combination may represent a new therapeutic option for advanced CTCL, particularly in mycosis fungoides. Trial Registration: ClinicalTrials.gov Identifier: NCT06037239.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lynn完成签到,获得积分10
6秒前
脑洞疼的应助被呵呵采纳,获得10
7秒前
10秒前
奋斗盼海发布了新的文献求助10
14秒前
震动的醉蓝完成签到,获得积分10
15秒前
21秒前
22秒前
Jianing发布了新的文献求助10
27秒前
呵呵发布了新的文献求助10
30秒前
33秒前
李健的小迷弟的应助被渟柠采纳,获得10
39秒前
wanci的应助被科研通管家采纳,获得10
40秒前
52秒前
渟柠发布了新的文献求助10
56秒前
urologywang完成签到 ,获得积分10
1分钟前
lili发布了新的文献求助20
1分钟前
淮安石河子完成签到 ,获得积分10
1分钟前
1分钟前
幸福的沛萍完成签到,获得积分10
1分钟前
研友_84mk0L发布了新的文献求助30
1分钟前
1分钟前
默岩1990完成签到,获得积分10
1分钟前
Yalby完成签到,获得积分10
1分钟前
1分钟前
缓慢的映天完成签到,获得积分10
1分钟前
研友_84mk0L发布了新的文献求助10
1分钟前
2分钟前
2分钟前
LTeresa发布了新的文献求助10
2分钟前
Repro发布了新的文献求助10
2分钟前
包容的初阳完成签到,获得积分10
2分钟前
2分钟前
2分钟前
Hello的应助被科研通管家采纳,获得10
2分钟前
研友_84mk0L完成签到,获得积分10
2分钟前
符聪完成签到,获得积分10
2分钟前
Xiaoqiang发布了新的文献求助20
2分钟前
3分钟前
向晚完成签到 ,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195122
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872869
捐赠科研通 7795077
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609